Products

Our Canadian Business Units

 

Medical Aesthetics

Allergan has an extensive Aesthetics & Medical Dermatology ​portfolio that provides medical experts and their patients with the most comprehensive, science-based product offerings available. From facial to breast enhancements, to the crylipolysis (acquisition of CoolSculpting), Allergan is the world leader in medical aesthetics.

Our technologically advanced medical dermatology products treat skin conditions and improve the appearance of skin. We're committed to providing medical experts and patients with products that can enhance lives by addressing individual treatment goals.​

Neurosciences

Allergan enhances the well-being of people around the world who suffer from a variety of neurological disorders and diseases in Neuroscience.

We are committed to providing treatments for neurological conditions and mental illnesses. We are dedicated to working with healthcare providers, patients, and caregivers. We support programs that provide more information and offer resources to guide patients and caregivers as they navigate these illnesses.​

Women’s Health

The Allergan Women's Health portfolio features a variety of products that focus on the unique needs of women. Our products help enhance the lives of women across Canada.

Gastroenterology

The Allergan Gastroenterology (GI) portfolio treats disorders of the digestive system. Our GI products improve the quality of life for patients whose daily lives are impacted by gastrointestinal disorders and their associated symptoms.

We're committed to providing medical specialists and their patients with products backed by science that have the potential to enhance lives by addressing GI symptoms and treatment goals.​

Eye Care

With a heritage of almost 70 years in discovering and developing new therapeutic agents to protect and preserve vision, eye care professionals and patients rely on Allergan products to treat a variety of eye conditions.

Our robust research and development investment upholds our unwavering commitment to advancing eye care treatments. Unfortunately, the prevalence of eye diseases is increasing as the population ages. Over the next decade, major progress will be made in treating such diseases and Allergan expects to be at the forefront of these advances.​